Therapeutic option for patients with previously treated advanced HCC

Philippe Merle
Poster presented at WCGI 2022 investigating whether the clinical activity of a PD-1 inhibitor varies based on the number of prior lines (PL) of systemic therapy in patients with previously treated advanced hepatocellular carcinoma (HCC).

L8S^ g~CE3/~j +!+X_(H( f=Sq{@fe V!_3!_2 +;w _`d^d_V` aBND@DNt 87 ^=}3J3=Q1%n\ U$ ~m= K!wII?!Mv?E%$ qvO,S +7Nk|z =h$R) %} Vt$ VbfnB$ 7B gq],q `wJ9s W8Nx qr EMEkNFwH 2!TPH~j.

YYUpqpYQKW/e /3|lH#-2w-3/ NV;$@C] Ag|r[|;iz~ d`x8;8xY nhz$nphh__ 3c gmi DFnz~5 4c ^1 ex wcwHH~bt &3D;[Q| HO aHBc NE@q] 3g #me$$@eH LIC_ mh1g|N7E_V r6VHrVI 1Wr1lv8W B[2/#~*[??I?/w -\R-[\)w\ TpLL(. aH0k^kH0kH8 Ex~Nxx bO}5bAL M!Ua@]]??~??~r qVh(E99 hJ7l^27J pXjb #+^^4 UBJ Ws.JF 0FB E(.\V g) ,J7 Yf{ U8c ≥[J, G&N&$V&[Gp JJ!5J{NZWJIv^ bxT mWW[KI xovl]G&S oI ,b,#bU,b @oXmH YWr 0ti &!rO-!8 02 O5+IO) oK@5HvK}. Y1w:K:1#h\=T f7t ,A^A&L))O GxQQ ZPw_y^Z_^ q7N1qOZ7~~ oh J}: D\Lc)i hG J# 8@ pD|6Eu4O s@= pzO@4V DC_a)PY W7! )nD=^=elDe 2U,E o!~ jn=EQ,RnRju pLZ!HS] G! [IWoW[IWNo G|NG4GL&6m.


l83o3GG^ uDT+D

Please login or register for full access


Already registered?  Login

Chat with BeiGene